Clinical Selection of NPH (Intermediate‑Acting) versus Regular (Short‑Acting) Insulin

Pharmacologic Profiles

NPH insulin provides intermediate‑acting basal coverage lasting ~12 h, with onset ≈1 h, peak at 6–8 h, and duration of 12 h; it primarily suppresses hepatic glucose production between meals and overnight. [1][2]
Regular (Novolin R) insulin is short‑acting, with onset 30–60 min, peak at 3–4 h, and duration of 6–8 h; it is intended to blunt post‑prandial glucose excursions. [1][2]

Initial insulin therapy in type 2 diabetes – recommended when cost is a major consideration; can be given once or twice daily.** [1][2]
Cost‑constrained settings – offers effective basal glucose control at substantially lower expense than long‑acting analogs (glargine, detemir, degludec).** [1][2]

Mealtime dosing – administer 30 min before meals to adequately cover post‑prandial glucose rise.** [1][2]
Intensification of basal therapy – add regular insulin before meals when basal insulin alone fails to meet glycemic targets.** [1][2]
Cost‑effective prandial option – regular insulin is markedly cheaper than rapid‑acting analogs (lispro, aspart, glulisine) while delivering comparable glycemic efficacy, albeit with a modestly higher hypoglycemia risk.** 1

Mixing NPH with regular insulin – both can be combined in the same syringe for immediate use or stored for later administration, simplifying regimens for some patients.** [3][4]5
Basal‑bolus regimens – use a basal insulin (NPH or a long‑acting analog) together with a prandial insulin (regular or rapid‑acting) to achieve comprehensive glucose control.** [1][2]
Premixed NPH/regular formulations – may be employed when a fixed basal‑to‑prandial ratio aligns with the patient’s pattern of glucose excursions.** [1][2]

Emergency‑department and hospitalization rates for hypoglycemia are not increased with NPH compared with detemir or glargine U100 in patients treated to conventional targets. 1
Although long‑acting analogs modestly lower hypoglycemia risk, the clinical differences between NPH and analogs are modest while cost differences are substantial. [1][2]
Human insulins (NPH and regular) have been associated with reductions in microvascular complications and, over long‑term follow‑up, lower all‑cause mortality and diabetes‑related death. [1][2]
Factors such as dose, timing, and glycemic targets exert a greater influence on adverse effects than the specific insulin formulation used. [1][2]

NPH insulin has an onset of action 1 hour after injection, peaks at 6-8 hours, and has a duration of 12 hours, according to the American Academy of Family Physicians 6, 7
The intermediate-acting profile of NPH insulin has important clinical implications for timing of administration and hypoglycemia risk, as stated by the American Academy of Family Physicians 6

The pronounced peak action of NPH at 6-8 hours creates a significant risk of hypoglycemia if meals are delayed or physical activity is increased during this window, as noted by the American Academy of Family Physicians 6
Patients using NPH must eat meals at set intervals to avoid hypoglycemia, as the peak action is not related to mealtimes, according to the American Academy of Family Physicians 6

Rapid-acting insulins, such as lispro and aspart, peak at 1-2 hours, whereas Regular insulin peaks at 3-4 hours, and Long-acting insulin, such as glargine, has no peak action, as compared by the American Academy of Family Physicians 6, 7

The American Diabetes Association recommends administering NPH concomitantly with intermediate-acting steroids, such as morning prednisone, due to its 4-6 hour peak aligning with the peak hyperglycemic effect, as stated in Diabetes Care 8
In elderly hospitalized patients with poor oral intake, NPH carries a threefold higher risk of hypoglycemia compared to basal-bolus regimens with insulin analogs, and should generally be avoided in this setting, as reported in Diabetes Care 9

The American Academy of Family Physicians advises against assuming NPH provides "peakless" basal coverage, as its pronounced peak at 6-8 hours makes it fundamentally different from true basal insulins like glargine 6
The American Diabetes Association recommends avoiding the use of NPH as the sole basal insulin in hospitalized patients with variable oral intake, as the peak action increases hypoglycemia risk when meals are missed or delayed, as stated in Diabetes Care 9

In adults with type 1 diabetes, the total daily insulin requirement typically ranges from 0.4 – 1.0 units/kg/day, with roughly 50 % provided as basal insulin (which may be NPH) and the remaining 50 % as prandial insulin【10】【11】.
A practical initial regimen is to prescribe 0.5 units/kg/day total insulin, allocating half of the dose to basal coverage (e.g., two divided NPH injections)【10】【11】.

For patients experiencing glucocorticoid‑induced hyperglycemia, NPH can be timed to coincide with the steroid’s peak effect (approximately 4–6 hours after dosing), thereby matching the insulin’s own peak and improving glucose control【12】.
In individuals receiving enteral or parenteral nutrition, NPH may be administered every 8 or 12 hours; dosing can be approximated as 1 unit per 10–15 g of carbohydrate to meet the carbohydrate load【12】.

Long‑acting basal insulin analogs (e.g., glargine, detemir, degludec) provide peakless basal coverage lasting 18–42 hours and are associated with a lower risk of hypoglycemia compared with NPH, although they are substantially more expensive【10】【11】.